(Q28578007)

31 January 2017

title

Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats (English)

1 reference

31 January 2017

1 reference

Martine P. Roudier

1

1 reference

31 January 2017

Steven D. Bain

series ordinal

2

1 reference

31 January 2017

William C. Dougall

series ordinal

3

1 reference

31 January 2017

publication date

1 January 2006

1 reference

Clinical & Experimental Metastasis

31 January 2017

published in

1 reference

31 January 2017

volume

23

1 reference

31 January 2017

issue

3-4

1 reference

31 January 2017

page(s)

167–175

1 reference

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo

31 January 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10585-006-9026-X

Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10585-006-9026-X

Bone cancer pain and the role of RANKL/OPG

21 January 2018

1 reference

12 December 2020

Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.

1 reference

12 December 2020

Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function

1 reference

12 December 2020

Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis

1 reference

12 December 2020

Zoledronic acid: a new parenteral bisphosphonate

1 reference

12 December 2020

Quantitative assessment of tactile allodynia in the rat paw

1 reference

12 December 2020

Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord

1 reference

12 December 2020

The pathophysiology of cancer-induced bone pain: current understanding

1 reference

12 December 2020

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

1 reference

12 December 2020

Alendronate Induces Antinociception in Mice, Not Related With Its Effects in Bone

1 reference

12 December 2020

The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

1 reference

12 December 2020

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

12 December 2020

Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer

1 reference

12 December 2020

Osteoprotegerin diminishes advanced bone cancer pain

1 reference

12 December 2020

Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice

1 reference

12 December 2020

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

1 reference

12 December 2020

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

1 reference

12 December 2020

Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons

1 reference

12 December 2020

Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain

1 reference

12 December 2020

Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis

1 reference

12 December 2020

A rat model of bone cancer pain

1 reference

12 December 2020

Serum osteoprotegerin levels in healthy controls and cancer patients

1 reference

12 December 2020

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

1 reference

12 December 2020

Long-term analgesic effect of clodronate in rodents

1 reference

12 December 2020

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

1 reference

12 December 2020

An acid sensing ion channel (ASIC) localizes to small primary afferent neurons in rats

1 reference

12 December 2020

Bone metastases--the clinical problem

1 reference

12 December 2020

Malignant bone pain: pathophysiology and treatment

1 reference

12 December 2020

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

1 reference

12 December 2020

Functional interactions between tumor and peripheral nerve: changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain

1 reference

12 December 2020

Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats.

1 reference

12 December 2020

Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain

1 reference

12 December 2020

10.1007/S10585-006-9026-X

Identifiers

DOI

1 reference

Dimensions Publication ID

31 January 2017

1041490200

0 references

1 reference